Literature DB >> 17699110

Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.

Mahmoud Toulany1, Michael Baumann, H Peter Rodemann.   

Abstract

Previous results showed an inducible radiation sensitivity selectively observable for K-RAS-mutated cell lines as a function of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor blockade of phosphatidylinositol 3-kinase (PI3K)-AKT signaling. Therefore, the role of K-Ras activity for a direct (i.e., through activation of PI3K by K-Ras) or an indirect stimulation of PI3K-AKT signaling (through K-Ras activity-dependent EGFR ligand production) was investigated by means of small interfering RNA and inhibitor approaches as well as ELISA measurements of EGFR ligand production. K-RASmt tumor cells presented a constitutively activated extracellular signal-regulated kinase-1/2 signaling, resulting in enhanced production and secretion of the EGFR ligand amphiregulin (AREG). Medium supernatants conditioned by K-RASmt tumor cells equally efficiently stimulated EGFR signaling into the PI3K-AKT and mitogen-activated protein kinase pathways. Knocking down K-Ras expression by specific small interfering RNA markedly affected autocrine production of AREG, but not PI3K-AKT signaling, after treatment of K-RAS-mutated or wild-type cells with EGFR ligands or exposure to ionizing radiation. These results indicate that PI3K-mediated activation of AKT in K-RASmt human tumor cells as a function of EGFR ligand or radiation stimulus is independent of a direct function of K-Ras enzyme activity but depends on a K-Ras-mediated enhanced production of EGFR ligands (i.e., most likely AREG) through up-regulated extracellular signal-regulated kinase-1/2 signaling. The data provide new differential insight into the importance of K-RAS mutation in the context of PI3K-AKT-mediated radioresistance of EGFR-overexpressing or EGFR-mutated tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699110     DOI: 10.1158/1541-7786.MCR-06-0297

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  36 in total

1.  Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.

Authors:  Ikhlas S Ahmed; Hannah J Rohe; Katherine E Twist; Rolf J Craven
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Proteomic analysis of energy metabolism and signal transduction in irradiated melanoma cells.

Authors:  Lu-Bin Yan; Kai Shi; Zhi-Tong Bing; Yi-Lan Sun; Yang Shen
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

3.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

4.  Somatic PI3K activity regulates transition to the spermatocyte stages in Drosophila testis.

Authors:  Samir Gupta; Krishanu Ray
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

Review 5.  [Molecular signaling pathways. Mechanisms and clinical use].

Authors:  N Cordes; F Rödel; H-P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

6.  ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.

Authors:  Mahmoud Toulany; Minjmaa Minjgee; Mohammad Saki; Marina Holler; Friedegund Meier; Wolfgang Eicheler; H Peter Rodemann
Journal:  Cancer Biol Ther       Date:  2013-12-09       Impact factor: 4.742

7.  The Role of Fgf Signaling on Epithelial Cell Differentiation in Mouse Vagina.

Authors:  Y U Hirano; Kentaro Suzuki; Taisen Iguchi; Gen Yamada; Shinichi Miyagawa
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 8.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 9.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Authors:  Martin L Sos; Mirjam Koker; Barbara A Weir; Stefanie Heynck; Rosalia Rabinovsky; Thomas Zander; Jens M Seeger; Jonathan Weiss; Florian Fischer; Peter Frommolt; Kathrin Michel; Martin Peifer; Craig Mermel; Luc Girard; Michael Peyton; Adi F Gazdar; John D Minna; Levi A Garraway; Hamid Kashkar; William Pao; Matthew Meyerson; Roman K Thomas
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.